Previous studies have shown that either genetic deletion or pharmacological inhibition of NOX4 reduces renal ROS levels leading to attenuation of experimental DKD, including key profibrotic and proinflammatory parameters [88]. Here, NOX4 is linked to diabetic kidney disease.